Asymptomatic Gaucher disease presented as Parkinsonism in 61 years old patient.
Objective: Gaucher disease is an inherited disease caused by a mutation in the glucocerebrosidase gene, causing visceral, hematologic, and skeletal involvement. [1] [2] We report…Response of extraocular movements in parkinson’s disease to levodopa: an electrooculographic perspective
Objective: To determine the response of latencies and amplitudes of saccadic movements to Levodopa in idiopathic Parkinson’s Disease. Background: Neurodegeneration in Parkinson’s Disease (PD) increases…Feasibility, Reliability and Value of Remote Levodopa Challenge Test in Parkinson’s Disease
Objective: To demonstrate the feasibility, reliability, and value of the remote L-dopa challenge test (LCT) in candidate screening for deep brain stimulation (DBS) in patients…Exercise and levodopa metabolism in Parkinson disease
Objective: The aim of our paper was to assess if standard physical exercise may change pharmacokinetics of levodopa/benserazide in patients with and without prior exposure…NLX-112 has favorable safety and tolerability and displays efficacy against levodopa-induced dyskinesia (LID) in Parkinson’s disease (PD)
Objective: To assess the safety, tolerability and preliminary efficacy of NLX-112 (a.k.a. befiradol) in patients with moderate to severe LID in PD: a randomized, double-blind,…What change to expect in duration of benefit per dose when switching from IR CD-LD to IPX203 (ER CD-LD)
Objective: To investigate if duration of benefit (“Good On” time) per dose during immediate-release (IR) carbidopa-levodopa (CD-LD) treatment predicts response to IPX203 conversion. Background: Levodopa’s…The diagnosis value of dopaminergic responsiveness of Parkinson’s disease： a systematic review and meta-analysis
Objective: aimed to confirm the diagnostic value/accuracy of levodopa and/or apomorphine challenge test in parkinsonian syndromes (PDS) to assess their value in the diagnosis of…Integrated analysis of phase 3 trials of foslevodopa/foscarbidopa demonstrated that majority of reported infusion site AEs including infections were non serious, mild to moderate in severity and did not result in treatment discontinuation.
Objective: To characterize reported infusion site infection adverse events (AEs) and their clinical management in patients with Parkinson’s disease (PD) treated with foslevodopa/foscarbidopa (LDP/CDP). Background:…Effect of levodopa on the interpretation of social interactions in people living with Parkinson’s disease
Objective: Better understand the social interactions by assessing the effect of oral levodopa on the social cognition abilities in fluctuating PD patients without significant cognitive disorder.…Home-based titration with Duodenal infusion of Levodopa in People with Parkinson’s disease: an observational feasibility study
Objective: Primary objectives were to assess the feasibility and safety of LCIG home titration with use of telemedicine-assisted (TM) technology, and patient/caregivers satisfaction. Secondly, to…
- « Previous Page
- 1
- …
- 10
- 11
- 12
- 13
- 14
- …
- 62
- Next Page »